Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP340738.RARb2RWBswax_HCQfsORZLMaejE0XbHuBnDkJaqLLyBt0130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP340738.RARb2RWBswax_HCQfsORZLMaejE0XbHuBnDkJaqLLyBt0130_provenance.
• NP768121.RAQCn-Xms8rUH9ottFA6A35xPSQ0oqKitvTma49iCA_Bs130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP768121.RAQCn-Xms8rUH9ottFA6A35xPSQ0oqKitvTma49iCA_Bs130_provenance.
• NP846213.RATxwoMbYi76raR93NFvBZw_LudbI0DvlHbVFFPul-FxY130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP846213.RATxwoMbYi76raR93NFvBZw_LudbI0DvlHbVFFPul-FxY130_provenance.
• NP564330.RAntrU2n7aZ2oxNfkZO14REBh8joNtvI9b4Qyqwc5Z0xs130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP564330.RAntrU2n7aZ2oxNfkZO14REBh8joNtvI9b4Qyqwc5Z0xs130_provenance.
• NP547192.RAzAUd_Z_XhruSbVbuymgZPlerjLX5xmPTHkGUn4nQlzg130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP547192.RAzAUd_Z_XhruSbVbuymgZPlerjLX5xmPTHkGUn4nQlzg130_provenance.
• NP311222.RAKzDMiSUhtCt2417MWA2mCBhRu17dm1ZlZ-dnsdv0pWg130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP311222.RAKzDMiSUhtCt2417MWA2mCBhRu17dm1ZlZ-dnsdv0pWg130_provenance.
• NP865707.RAC_3pCetS2tT_JsHrjZ9BWqwLwy7jts-sVIKhYimNOkw130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP865707.RAC_3pCetS2tT_JsHrjZ9BWqwLwy7jts-sVIKhYimNOkw130_provenance.
• NP865693.RAdVGnprwV1kt_jKix6k7zXoQ4WWdf3-FaEdxcYXWy_tI130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP865693.RAdVGnprwV1kt_jKix6k7zXoQ4WWdf3-FaEdxcYXWy_tI130_provenance.
• NP456277.RA4JpZxigQF9XW5Rv-WWAD3-B0a6CzZLK_Ali3uCi42yw130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456277.RA4JpZxigQF9XW5Rv-WWAD3-B0a6CzZLK_Ali3uCi42yw130_provenance.
• assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1015586.RAqdAnfmUK4VAAxfcHKfDRKaR7S5Vml3jdQUsxtIrZfbE130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1015586.RAqdAnfmUK4VAAxfcHKfDRKaR7S5Vml3jdQUsxtIrZfbE130_provenance.
• NP1015599.RAuY-eRLyGuXQp_D6F0GGjdWPultDCxlNZK5c_sioy9i4130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1015599.RAuY-eRLyGuXQp_D6F0GGjdWPultDCxlNZK5c_sioy9i4130_provenance.
• assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP456276.RAsmFvDZoDjVNffiXjFAfLFjxFxqaux4g9e8v_a0i4w8o130_assertion description "[Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP456276.RAsmFvDZoDjVNffiXjFAfLFjxFxqaux4g9e8v_a0i4w8o130_provenance.